Prophylactic and therapeutic vaccine against Pseudomonas aeruginosa keratitis using bacterial membrane vesicles

被引:12
|
作者
Ito, Saori [1 ]
Nakamura, Jutaro [1 ]
Fukuta, Michiko [1 ]
Ura, Takehiro [1 ]
Teshigawara, Takeshi [2 ]
Fukushima, Jun [3 ]
Mizuki, Nobuhisa [1 ]
Okuda, Kenji [4 ,5 ,6 ]
Shimada, Masaru [4 ]
机构
[1] Yokohama City Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Yokohama, Kanagawa 2360004, Japan
[2] Yokosuka Chuoh Eye Clin, Dept Ophthalmol, Yokosuka, Kanagawa 2380008, Japan
[3] Akita Prefectural Univ, Dept Microbiol, Akita 0100195, Japan
[4] Yokohama City Univ, Grad Sch Med, Dept Mol Biodef Res, Yokohama, Kanagawa 2360004, Japan
[5] Okuda Vaccine Res Inst, Yokohama, Kanagawa 2350045, Japan
[6] Yokohama City Univ, Yokohama, Kanagawa 2360004, Japan
关键词
Vaccine; Pseudomonas aeruginosa keratitis; membrane vesicles (MVs); Mouse model; PASSIVE IMMUNOTHERAPY; PROTEOMIC ANALYSIS; PROTECTION; IMMUNIZATION; MICE; INFECTIONS; ADENOVIRUS; VIRULENCE; PROTEASES; IMPACT;
D O I
10.1016/j.vaccine.2021.04.035
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose: Pseudomonas aeruginosa (P. aeruginosa) infection is one of the major causes of keratitis. However, effective prophylactic and therapeutic vaccines against P. aeruginosa keratitis have yet to be developed. In this study, we explored the use of P. aeruginosa membrane vesicles (MVs) as a prophylactic vaccine as well as the use of immune sera derived from P. aeruginosa MV-immunized animals as a treat-ment for P. aeruginosa corneal infections in C57BL/6 mice. Methods: C57BL/6 mice were intramuscularly immunized with P. aeruginosa MVs; the mouse corneas were then scarified and topically infected with several P. aeruginosa strains, followed by determination of corneal clinical score and corneal bacterial load. Next, immune sera derived from P. aeruginosa MV-immunized ICR mice were administered intraperitoneally to na & iuml;ve C57BL/6 mice, followed by topical P. aeruginosa challenge. Finally, the immune sera were also used as a topical treatment in the mice with established P. aeruginosa corneal infections. Results: P. aeruginosa-specific IgG and IgA antibodies induced by intramuscular immunization were detected not only in the sera but also in the eye-wash solution. Both active and passive immunization significantly inhibited P. aeruginosa corneal infection. Finally, topical treatment with immune sera in the mice with established P. aeruginosa corneal infections notably decreased the corneal clinical score and corneal bacterial load. Conclusions: P. aeruginosa keratitis can be attenuated by vaccination of P. aeruginosa MVs and topical application of P. aeruginosa MV-specific immune sera. (c) 2021 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3152 / 3160
页数:9
相关论文
共 50 条
  • [1] ORAL VACCINATION AND MULTIVALENT VACCINE AGAINST PSEUDOMONAS-AERUGINOSA KERATITIS
    GERKE, JR
    NELSON, JS
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1977, 16 (01) : 76 - 80
  • [2] An X-ray inactivated vaccine against Pseudomonas aeruginosa Keratitis in mice
    Jiang, Boguang
    Luo, Yingjie
    Yan, Naihong
    Shen, Zhixue
    Li, Wenfang
    Hou, Chen
    Xiao, Lirong
    Ma, Cuicui
    Zhang, Li
    Chen, Yanwei
    Cheng, Xingjun
    Lian, Mao
    Ji, Chengjie
    Zhu, Ziyi
    Wang, Zhenling
    VACCINE, 2023, 41 (32) : 4700 - 4709
  • [3] Topical Glycyrrhizin Is Therapeutic for Pseudomonas aeruginosa Keratitis
    Ekanayaka, Sandamali A.
    McClellan, Sharon A.
    Barrett, Ronald P.
    Hazlett, Linda D.
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 34 (03) : 239 - 249
  • [4] Topical glycyrrhizin is therapeutic for Pseudomonas aeruginosa keratitis
    Ekanayaka, Sandamali Amarasingha
    McClellan, Sharon A.
    Barrett, Ronald P.
    Hazlett, Linda
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [5] Multifunctional membrane vesicles in Pseudomonas aeruginosa
    Tashiro, Yosuke
    Uchiyama, Hiroo
    Nomura, Nobuhiko
    ENVIRONMENTAL MICROBIOLOGY, 2012, 14 (06) : 1349 - 1362
  • [6] An outer membrane protein preparation as a vaccine against Pseudomonas aeruginosa infection
    Park, WJ
    Cho, YJ
    Ahn, DH
    Jung, SB
    Lee, NG
    Kim, HS
    Hahm, KS
    Kim, YS
    JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 1997, 7 (02) : 144 - 150
  • [7] Pseudomonas aeruginosa LasA protease as a therapeutic agent in Staphylococcal keratitis
    Barequet, IS
    Safrin, M
    Bourla, N
    Ben Simon, GJ
    Ohman, DE
    Rosner, M
    Kessler, E
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 : U548 - U548
  • [8] Using dendritic cells as therapeutic or prophylactic vaccine against HCV
    Weigand, Kilian
    Voigt, Franziska
    Eisenbach, Christoph
    Hoyler, Birgit
    Stremmel, Wolfgang
    Encke, Jens
    HEPATOLOGY, 2007, 46 (04) : 856A - 856A
  • [9] Bacterial membrane vesicles for vaccine applications
    Krishnan, Nishta
    Kubiatowicz, Luke J.
    Holay, Maya
    Zhou, Jiarong
    Fang, Ronnie H.
    Zhang, Liangfang
    ADVANCED DRUG DELIVERY REVIEWS, 2022, 185
  • [10] Long-Distance Delivery of Bacterial Virulence Factors by Pseudomonas aeruginosa Outer Membrane Vesicles
    Bomberger, Jennifer M.
    MacEachran, Daniel P.
    Coutermarsh, Bonita A.
    Ye, Siying
    O'Toole, George A.
    Stanton, Bruce A.
    PLOS PATHOGENS, 2009, 5 (04)